Introduction: F-18 Fluciclovine (AxuminTM) is a new positron emission tomography (PET) agent used for patients suspected of having prostate cancer recurrence based on prostate specific antigen (PSA) l..
Introduction: F-18 Fluciclovine (AxuminTM) is a new positron emission tomography (PET) agent used for patients suspected of having prostate cancer recurrence based on prostate specific antigen (PSA) levels following prior treatment of prostate cancer. This presentation provides a case-based discussion on what the clinician needs to know, including a background on AxuminTM, how to interpret an AxuminTM study, and pitfalls to be aware of during interpretation. Goals and Objectives: Understand the indications for the use of F-18 Fluciclovine. Gain a basic understanding on the mechanism of localization of F-18 Fluciclovine. Learn the normal biodistribution and how to interpret an F-18 Fluciclovine study as well as understanding common pitfalls to interpretation. Discussion: This presentation will discuss the indications, mechanism of localization, normal distributions, and a suggested interpretation criteria for F-18 Fluciclovine PET studies. A brief discussion will be made comparing F-18 Fluciclovine with other nuclear medicine agents used in prostate cancer imaging. Cases presented will illustrate cases of metastatic disease in the setting of biochemical recurrence as well as interesting cases of false positive studies. There will also be a discussion on pitfalls to interpretation. Conclusion: F-18 Fluciclovine is a new and effective PET agent that can be used to diagnose local recurrent or distant metastatic disease in patients with a history of prostate cancer. Knowledge of pitfalls as well as potential false positive and false negative uptake patterns is crucial for accurate diagnosis in these patients.